Peter Cherutich MPH, PhD

Clinical Assistant Professor, Global Health, University of Washington

Senior Deputy Director of Medical Services, Kenya Ministry of Health

Dr. Peter Cherutich, MPH, PhD, is a Senior Deputy Director of Medical Services at the Kenya Ministry of Health and previously was the Director of Preventive and Promotive Health Services. Before stepping into this position, he was a program manager, at the National AIDS and STI Control Programme (NASCOP). Dr. Cherutich is a pioneer implementation scientist and graduated with a PhD in Global Health-Implementation Science from the University of Washington in 2015. His research interests revolve around optimizing HIV prevention options in Kenya and his portfolio includes pioneering work among people who inject drugs (PWID). In the context of micro-elimination of Hepatitis C among PWID Dr. Cherutich established research collaborations with the University of Washington (UW), Yale University and Gilead Sciences. His PhD work published in the Lancet HIV catalyzed WHO recommendations in assisted HIV partner notification services and is the basis for scaling up of partner notification services in PEPFAR and Global Fund supported countries including Kenya. He also has interests in young and adolescent women to improve their knowledge of HIV status and to establish mechanisms for resilience and reduce risk of HIV acquisition. In partnership with Georgetown University he is on initial discussions on implementation science research work around HIV cure and some preparatory work that would need to be done before it becomes available.

Publications

  1. Wamuti, B, Jamil, MS, Siegfried, N, Ford, N, Baggaley, R, Johnson, CC et al.. Understanding effective post-test linkage strategies for HIV prevention and care: a scoping review. J Int AIDS Soc. 2024;27 (4):e26229. doi: 10.1002/jia2.26229. PubMed PMID:38604993 PubMed Central PMC11009370.
  2. Akiyama, MJ, Riback, LR, Nyakowa, M, Musyoki, H, Lizcano, JA, Muller, A et al.. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya. Int J Drug Policy. 2023;113 :103959. doi: 10.1016/j.drugpo.2023.103959. PubMed PMID:36758335 PubMed Central PMC10034760.
  3. Young, PW, Musingila, P, Kingwara, L, Voetsch, AC, Zielinski-Gutierrez, E, Bulterys, M et al.. HIV Incidence, Recent HIV Infection, and Associated Factors, Kenya, 2007-2018. AIDS Res Hum Retroviruses. 2023;39 (2):57-67. doi: 10.1089/AID.2022.0054. PubMed PMID:36401361 PubMed Central PMC9942172.
  4. Stone, J, Fraser, H, Walker, JG, Mafirakureva, N, Mundia, B, Cleland, C et al.. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya. AIDS. 2022;36 (15):2191-2201. doi: 10.1097/QAD.0000000000003382. PubMed PMID:36111533 PubMed Central PMC9671825.
  5. Seu, R, Riback, LR, Nyakowa, M, Lizcano, J, Musyoki, H, Ross, J et al.. Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya. Glob Public Health. 2022;17 (12):3627-3637. doi: 10.1080/17441692.2022.2110919. PubMed PMID:35941717 PubMed Central PMC9898079.
Search PubMed

Comments are closed.